	US 12,226,455 B2
	Medical composition for treating cardiac wasting and cachexia
Thomas Bernd Dschietzig, Berlin (DE)
Assigned to RELAXERA PHARMAZEUTISCHE GMBH & CO. KG, Bensheim (DE)
Appl. No. 17/776,749
Filed by RELAXERA Pharmazeutische GmbH & Co. KG, Bensheim (DE)
PCT Filed Nov. 16, 2020, PCT No. PCT/EP2020/082308 § 371(c)(1), (2) Date May 13, 2022, PCT Pub. No. WO2021/094626, PCT Pub. Date May 20, 2021.
Claims priority of application No. 10 2019 131 002.4 (DE), filed on Nov. 16, 2019.
Prior Publication US 2022/0401522 A1, Dec. 22, 2022
Int. Cl. A61K 38/22 (2006.01); A61P 9/02 (2006.01); A61P 9/04 (2006.01)

CPC A61K 38/2221 (2013.01) [A61P 9/02 (2018.01)]

6 Claims

1. A method of treating a patient diagnosed with cardiac wasting or cardiac cachexia or being at risk of cardiac wasting, comprising the administration of an effective amount of human relaxin-2, wherein said method comprises administering human relaxin-2 at 10 to 100 μg relaxin-2/kg body weight/day.